Objective: This study was designed to investigate treatment efficacy and side effects of concomitant Aisu®(docetaxel) with three-dimensional conformal external beam radiotherapy for the treatment of inoperablepatients with esophageal cancer. Methods: Inoperable patients were treated with three-dimensional conformalexternal beam radiotherapy (5/week, 2 GY/day, and total dose 60GY) plus docetaxel (30-45 mg/m2, iv, d1, 8). Results: Twenty eight patients met the study eligibility criteria and the response rate was evaluated accordingto RICIST guidelines. Among 28 patients, 2 achieved CR, 22 PR, 3 SD and 1 patient was documented PD. Mildgastrointestinal reaction and bone marrow suppression were also documented. All treatment related side effectswere tolerable. Conclusion: Three-dimensional conformal external beam radiotherapy combined with docetaxelis an active and safe regimen for inoperable patients with esophageal cancer.
(2012). Phase II Study of Docetaxel (Aisu®) Combined with Threedimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. Asian Pacific Journal of Cancer Prevention, 13(12), 6523-6526.
MLA
. "Phase II Study of Docetaxel (Aisu®) Combined with Threedimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer". Asian Pacific Journal of Cancer Prevention, 13, 12, 2012, 6523-6526.
HARVARD
(2012). 'Phase II Study of Docetaxel (Aisu®) Combined with Threedimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer', Asian Pacific Journal of Cancer Prevention, 13(12), pp. 6523-6526.
VANCOUVER
Phase II Study of Docetaxel (Aisu®) Combined with Threedimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. Asian Pacific Journal of Cancer Prevention, 2012; 13(12): 6523-6526.
)